New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 2, 2014
10:16 EDTWTW, AVP, TRLA, EXPE, MACKOptions with decreasing implied volatility: MACK EXPE TRLA AVP WTW
News For MACK;EXPE;TRLA;AVP;WTW From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2015
05:27 EDTEXPEExpedia app now available on Apple watch
Subscribe for More Information
April 21, 2015
09:22 EDTMACKOn The Fly: Pre-market Movers
Subscribe for More Information
08:10 EDTMACKMerrimack to present updated clinical data from Phase 1 study of MM-141
Merrimack Pharmaceuticals announced updated clinical data from a multi-arm Phase 1 study of MM-141, a bispecific antibody targeting IGF-1R and ErbB3. The data were presented in an oral session at the 2015 American Association for Cancer Research Annual Meeting in Philadelphia, PA. The trial evaluated the safety and tolerability of MM-141 as a monotherapy and in combination with everolimus or with nab-paclitaxel and gemcitabine in patients with advanced solid tumors.
06:01 EDTMACKMerrimack price target raised to $16 from $13 at Mizuho
Subscribe for More Information
April 20, 2015
16:07 EDTMACKMerrimack announces final clinical results for MM-302 Phase 1 study
Merrimack Pharmaceuticals announced updated and final clinical results for the Phase 1 study of MM-302, a novel HER2-targeted liposomal doxorubicin, in HER2-positive metastatic breast cancer. Data described the safety and promising clinical activity of MM-302 in patients with advanced HER2-positive metastatic breast cancer. Results from the trial showed that the group of patients treated with 30 mg/m2 or more of MM-302 alone, in combination with trastuzumab or with trastuzumab and cyclophosphamide, had a median progression free survival, or mPFS, of 7.6 months and an overall response rate, or ORR, of 11%. Of note, 25 patients who had not been previously treated with anthracyclines had an mPFS of 11 months and an ORR of 24%. The most frequent adverse events occurring in greater than 20% of the population in this Phase 1 study were constipation, cough, decreased appetite, diarrhea, dyspnea, fatigue, nausea, neutropenia, stomatitis and vomiting. The most common Grade 3/4 adverse event was neutropenia observed in 8 patients. Six out of 69 patients 9% had protocol-defined asymptomatic declines in left ventricular ejection fraction, or LVEF. In 1 of the 6 patients, this was reported as a Grade 1 cardiac failure that was possibly related to study treatment. Merrimack is currently enrolling the HERMIONE study that is designed to support a potential application for accelerated approval in the U.S. and conditional marketing authorization in the E.U. The HERMIONE study is for HER2-positive, metastatic breast cancer patients who are anthracycline-naive and have not been previously treated with pertuzumab and T-DM1-containing regimens.
07:20 EDTMACKAmerican Association for Cancer Research to hold annual meeting
Subscribe for More Information
April 17, 2015
16:31 EDTAVPStocks end week lower amid earnings reports, fear about Greece, China
Subscribe for More Information
April 15, 2015
12:33 EDTAVPStocks with call strike movement; ZIOP AVP
Ziopharm (ZIOP) October 14 call option implied volatility increased 8% to 97, Avon Products (AVP) July 11 call option implied volatility decreased 2% to 57 according to IVolatility.
05:48 EDTAVPStocks with implied volatility movement; WUBA AVP
Subscribe for More Information
April 14, 2015
16:53 EDTAVPOn The Fly: Top stock stories for Tuesday
Stocks on Wall Street were mixed for the day, beginning the session in positive territory helped by better than expected earnings reports from JPMorgan (JPM), Johnson & Johnson (JNJ), and Wells Fargo (WFC). The early economic data was slightly below Wall Street expectations and became a headwind for the market. By the end of the first hour of trading the market had turned negative, and it spent the remainder of the day trading in mixed fashion. ECONOMIC EVENTS: In the U.S., retail purchases for March advanced 0.9%, bouncing up from a 0.5% decline in February. However, economists had predicted a 1.1% growth after improvements on last month's weather. The producer price index grew 0.2% for March, in line with consensus estimates. Core PPI grew 0.2% versus expectations of 0.1% growth. The International Monetary Fund's World Economic Outlook Report trimmed U.S. growth forecast to 3.1% from its previous outlook of 3.6%, while global forecast was left unchanged at 3.5%. COMPANY NEWS: Avon (AVP) surged 66c, or 8.24%, to $8.67 following a Wall Street Journal report that the company is exploring strategic alternatives, including potentially selling its North American business, though a Bloomberg report later in the day claimed the company is not conducting a formal sale process... Nokia (NOK) confirmed it is in "advanced discussions" to buy French telecom firm Alcatel-Lucent (ALU), prompting French President Francois Hollande to schedule meetings with leaders from both companies. Later in the day, the French government announced it supports the potential deal, with French Economy Minister Emmanuel Macron stating Nokia reassured officials by detailing "clear undertakings." Nokia fell 34c, or 4.1%, to $7.96 at the close, while Alcatel jumped 58c, or 13.33%, to $4.93. MAJOR MOVERS: Among the notable gainers was 58.com (WUBA), which rallied 33.52%, or $17.04, to $67.87 after the Financial Times reported the company has signed a memorandum of understanding to merge with rival classifieds service Ganji.com. Also higher was PartnerRe (PRE), which advanced 8.49% to $129.25 after EXOR proposed to acquire the company for $130.00 per share in cash, valuing PartnerRe at $6.4B. Following earnings, JPMorgan (JPM) advanced 1.56% to $63.04 after beating expectations, while Wells Fargo (WFC) fell 0.73% and Johnson & Johnson fell 0.03% after reducing its FY15 earnings guidance. Among the noteworthy losers was Arrowhead Research (ARWR), which tumbled 7.75% after Jefferies downgraded the stock to Hold and lowered its price target to $9 from $30. The firm said that while ARC-520 offers the potential for a Hepatitis B virus functional cure, it prefers to wait for multi-dosing data. Also lower was Norfolk Southern (NSC), which dropped 4.18% to $100.49 and was downgraded to Hold at TD Securities following first quarter guidance that fell below expectations. INDEXES: The Dow rose 59.66, or 0.33%, to 18,036.70, the Nasdaq lost 10.96, or 0.22%%, to 4,977.29, and the S&P 500 advanced 3.41, or 0.16%, to 2,095.84.
14:45 EDTAVPAvon said not to be conducting formal sale process, Bloomberg says
12:59 EDTAVPAvon Products reviewing strategic options, WSJ reports
Subscribe for More Information
12:59 EDTAVPAvon Products volatility elevated into exploring strategic alternatives report
Avon Products overall option implied volatility of 59 compares to its 26-week average of 55 according to Track Data, suggesting large price movement into a WSJ reported the company is exploring strategic alternatives.
12:55 EDTAVPAvon Products resumes trading, shares up 74c to $8.75
Subscribe for More Information
12:55 EDTAVPAvon Products halted for volatility after jumping on WSJ report
Shares of Avon Products halted for volatility after the Wall Street Journal reported the company is exploring strategic alternatives, including a possible sale of its North America business. The stock jumped 69c to $8.70.
12:52 EDTAVPAvon Products reviewing strategic alternatives, Dow Jones says
Subscribe for More Information
09:17 EDTMACKMerrimack management to meet with Brean Capital
Subscribe for More Information
April 13, 2015
17:17 EDTAVPAvon Products postpones Investor Day to fall 2015
Avon Products announced that it has decided to postpone to Fall 2015 its Investor Day that the company was originally scheduled to host on May 13. The decision to postpone the meeting follows the recent appointment of James Scully as the company's CFO, to allow the company adequate time to prepare for a more robust discussion at the meeting. Further details, including webcast information, will be announced closer to the event. Avon will provide an update on its turnaround progress when it reports first-quarter 2015 financial results on April 30.
April 12, 2015
15:56 EDTAVPAvon investors could be rewarded in coming years, Barron's says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use